Viral genotypic responses to recombinant vaccine therapy in HIV-1 infected children

S. M. Essajee*, Ram Yogev, H. Pollack, B. Greenhouse, K. Krasinski, W. Borkowsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Little is known about the pattern of viral evolution over time in individuals chronically infected with HIV. Diversity within the viral envelope over a six-month period was evaluated by heteroduplex tracking assays (HTA's) performed on 11 stable HIV-1 infected children aged 8-141 months. All had been enrolled into ACTG protocol 218 - a double-blinded trial of recombinant HIV-1 glycoprotein vaccines. Eight had received vaccine and three placebo. HTA analysis showed that at baseline, all patients were infected with more than 1 viral quasispecies. Viral diversification over the 6 month period of study was seen in 5 of 11 patients (45%). Three of these had received vaccine and two placebo. Diversifies were older than non-diversifiers, average age 77 months vs. 25 months (p=ns). No difference in CD4 percentage at baseline (31.2 vs. 36), or percentage change during the study (-3.8 vs. -7.1) was noted between the two groups. In conclusion, stable HIV-1 infected children with relatively healthy immune function tend to harbor multiple env quasispecies. This is consistent with the concept that immune pressure drives viral evolution. In this small sample, diversification was associated with age but not with vaccine therapy. Glycoprotein vaccination in this group of immunologically intact children did not seem to generate a selective pressure to drive quasispecies evolution.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Issue number2
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Viral genotypic responses to recombinant vaccine therapy in HIV-1 infected children'. Together they form a unique fingerprint.

Cite this